Primary liver cancer is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. We review hypotheses of the cell of origin of liver tumorigenesis, and clarify the classes of liver cancer, based on molecular features and how these affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. 
Primary liver cancer is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. We review hypotheses of the cell of origin of liver tumorigenesis, and clarify the classes of liver cancer, based on molecular features and how these affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. The molecular and clinical features of HCC vs iCCA are distinct, although they have overlapping risk factors and pathways of oncogenesis. A better understanding of the cell types originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis and therapeutic options. Molecular studies have identified adult hepatocytes as the cell of origin. These cells have been proposed to transform directly into HCC cells (via a sequence of genetic alterations), to de-differentiate into hepatocyte precursor cells (which then become HCC cells that express progenitor cell markers), or to transdifferentiate into biliary-like cells (which give rise to iCCA). Alternatively, progenitor cells also give rise to HCCs and iCCAs with markers of progenitor cells. Advances in genome profiling and next-generation sequencing have led to the classification of HCCs based on molecular features, and assigned them to categories such as proliferation-progenitor, proliferation-transforming growth factor beta, and Wnt-catenin beta 1 . iCCAs have been assigned to categories of proliferation and inflammation. Overall, proliferation subclasses are associated with a more aggressive phenotype and poor outcome of patients, although more specific signatures have refined our prognostic abilities. Analyses of genetic alterations have identified those that might be targeted therapeutically, such as fusions in the FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 30% of HCCs). Further studies of these alterations are needed before these can be used as biomarkers in clinical decision Liver cancer is the second most common cause of cancer-related death worldwide and one of the few neoplasms whose incidence and mortality have been steadily increasing 1, 2 , with the highest increase in mortality in the United States (US) during the last 2 decades (Figure 1 3 ).
Liver cancer comprises a heterogeneous group of malignant tumors with different histologic features and unfavorable prognosis that range from hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) to mixed hepatocellular-cholangiocarcinoma (HCC-CCA), fibrolamellar HCC, and the pediatric neoplasm hepatoblastoma 4, 5 . Among these, HCC and iCCA are the most common primary liver cancers, whereas the other neoplasms, including mixed HCC-CCA tumors 5 , account for less than 1% of cases. The burden of liver cancer is increasing globally-there could be 1 million cases by 2030 6 . It is not clear how direct-acting antiviral (DAA) agents, which can cure hepatitis C virus (HCV) infection, will affect the burden of HCC. It has been estimate that curing more than 90% of patients with HCV infection would eliminate 15% of HCC cases in the US 7 . However, there is debate over the effects of DAA agents on progression of HCC [8] [9] [10] [11] . HCC alone accounts for 90% of all primary liver cancer cases with nearly 800,000 new annual cases 2 . Its highest incidence is in Asia and Sub-Saharan Africa due to the high prevalence of hepatitis B virus (HBV) infection 6 . Unlike other cancers, the main risk factors associated with HCC are well defined and include viral hepatitis (B and/or C), alcohol abuse and non-alcoholic fatty liver disease in patients with metabolic syndrome and diabetes. Other co-factors of HCC development, such as aflatoxin B1 and tobacco, increase the incidence of the disease if other common risk factors are present 12 .
iCCA is the second most common liver cancer, with the highest incidence in Southeast Asia (30-40 cases/10 5 inhabitants) and low incidence in Western countries (fewer than 5 cases/10 5 inhabitants) 13 . Nevertheless, steady increases have been reported 13, 14 . [23] [24] [25] ( Figure 3 ). In parallel, progenitor cells may also give rise to HCCs and iCCA with progenitor-like features, whereas adult cholangiocytes, which lack the plasticity and transforming capacity of hepatocytes, can only give rise to iCCAs 26 .
Progenitor cells and hepatocytes in liver regeneration
Adult stem cells or somatic stem cells are defined as undifferentiated cells with limitless replicative potential. They can differentiate into all or some specialized cell types, and their primary role is to sustain physiological tissue turnover and to direct tissue repair upon different types of injury 27 . Stem cell compartments have been successfully identified in several adult tissues with fast turnover, including the gastrointestinal tract, skin, and bone marrow. Because of their self-renewal potential and long lifespan, these cells are thought to be more prone to malignant transformation 28, 29 and have been identified as the cell of origin of cancer in several organs, for example skin and intestine [30] [31] [32] . Unlike these organs, however, cells of the adult liver have relatively slow turnover (a period of several months), with an average hepatocyte life span ranging from 200 to 300 days 33, 34 . In this context, the contribution of stem cells to liver turnover is unclear (reviewed in ref. 35 ).
Hepatocytes are quiescent in normal liver, but their turnover in the liver dramatically accelerates upon hepatic injury or after a significant reduction of liver mass such as following partial hepatectomy. Under these conditions, adult hepatocytes have enormous proliferative potential (capacity to replicate more than 50 times), a feature that has enabled human liver organ donor transplantation as a standard procedure to treat end-state liver disease [33] [34] [35] . . In addition, a recent study has demonstrated that hepatocyte-specific p62 expression promotes c-MYC induction, mTORC1 activation and HCC initiation 70 .
Adult hepatocytes, however, have additional properties consistent with a cell that originates cancer. These include their remarkable plasticity, which entails their capacity to de-differentiate into a progenitor state and then can restore the hepatocyte pool 25 . Mature hepatocytes can dedifferentiate following loss of the tumor suppressor TP53, which yields nestin-positive progenitor-like cells that can expand and generate primary liver cancers after acquiring lineagespecific oncogenic lesions, such as mutations in WNT (in HCC) or Notch (in iCCA) 52 ( Table 1 ).
In addition, adult hepatocytes can also trans-differentiate into biliary-like cells ( Figure 3 (Table 1 ).
There is evidence that different cell types can serve as the cell of origin for primary liver cancers [8] [9] [10] [11] . If confirmed, the potential role of immune system should be explored, because rapid clearance of HCV in patients with chronic infection for years might affect immune surveillance.
Immune therapies
The immune microenvironment of HCC is characterized by the co-existence of immune responses leading to both immunogenicity and tolerance 87 . HCCs promote immunotolerance through the release of cytokines such as interleukin 10 (IL10) and transforming growth factor beta (TGFB). The tumors and tumor-infiltrating immune cells also express immune regulators such as programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T-lymphocyte protein 4 (CTLA4), which suppress the anti-tumor immune response, allowing tumor growth and progression 87, 88 . Tumors with immune infiltrates have been associated with longer survival times and reduced relapse after resection and transplantation 2, 88 . In addition, some HCC cases of spontaneous regression have been linked to immune-mediated mechanisms 
Reaching a consensus
The development of a molecular classification of HCC has paralleled the progress in genomic profiling technologies, and is extensively reviewed elsewhere 97 . Initial studies relied on differences in gene expression patterns determined by microarrays, whereas more recent, sequencing-based studies used mutation signatures to classify HCCs heterogeneous with significant enrichment in signaling pathways related to proliferation, such as insulin like growth factor 1 (IGF1) 98 signaling. It might also be possible to use alternative anti-tumor approaches, such as immune checkpoint inhibitors, or strategies to antagonize the most prevalent genetic defects found in HCCs, such as mutations in TERT, TP53 and CTNNB1.
Molecular Subclasses of iCCA
There is no effective treatment for iCCA. Reasons include our poor understanding of its pathogenesis and the lack of studies conducted specifically in patients with iCCA, apart from patients with all biliary tract cancers 13, 14 ; this is important because iCCAs are characterized by a distinct set of mutations 14 . iCCAs were only recently recognized as a distinct entity with both its An independent whole-transcriptomic analysis of a large cohort including iCCA and extrahepatic cholangiocarcinomas also confirmed the existence of the two prognostic CCA molecular subtypes 123 . , although this finding has not been confirmed 95, 126, 134 . Early-phase clinical trials testing selective FGFR inhibitors in advanced iCCA patients carrying alterations in FGFR2 are underway (NCT02150967 and NCT01752920) 136, 137 . These studies reported an objective response rate of approximately 15% (a signal of efficacy) and manageable safety profile 136 . The discovery that FGFR2 fusions can promote development of iCCAs has been quickly translated to clinical trials. Fusions of the FGFR2 gene might be used as biomarker to select patients for treatment with these agents. . FLC has less chromosomal aberrations compared to HCC or iCCA without recurrent high-level amplifications or deletions.
Molecular Features of Uncommon Tumors
Hepatoblastoma is the most frequent primary liver tumor in children younger than 5 years old.
Like FLC, background liver disease is rare in these patients. WNT signaling plays a major role, . A comprehensive integrative genomic analysis of 18 mixed HCC-CCA subtypes defined 3 molecular types (CLC, stem cell, and classical subtype) 146 . In particular, the CLC subtype, despite being grouped, based on histology, within the stem cell-feature subtype, has a unique molecular profile, with biliary traits, low levels of chromosome instability, and activation of TGFB and inflammation-related signaling pathtways 146 .
Challenges in tumor heterogeneity
Liver tumors have a high degree of molecular heterogeneity, not only among patients with the same types of tumors, but also within regions within the same tumor or tissue 147 . Expert recommendations and consensus definitions have been established to better address the extent and role of cancer heterogeneity in oncology research 148 .
From a clinical perspective, molecular heterogeneity should be considered within the concepts of trunk and branch, and driver and passenger mutations. Trunk mutations (mutations that occur early in tumorigenesis) can be found in every cancer cell of a tumor 
Prognostic Markers
Molecular biomarkers have many applications in cancer. The can improve clinical decision making by helping to predict a patient's outcome, select the patients most likely to respond to a specific treatment, and avoid treatments not likely to be effective. Unlike other cancers such as breast 149 and colorectal 150 cancers, HCC has no molecular markers that have been incorporated into clinical management.
As a general rule, clinical practice guidelines include recommendations based on a specified set of metrics, which rate the level of evidence and the strength of recommendations for each statement; the higher the evidence, the stronger the recommendation. . Level D evidence comes from studies of convenience, in which specimens were collected for unknown reasons and happen to be available for assay.
Gene signatures associated with risk of HCC development may have a more direct application ( Table 2) 100, 102, [158] [159] [160] [161] . For instance, a 186-gene signature in liver tissues was able to predict occurrence of HCC 158 in patients with hepatitis C-related early-stage cirrhosis, and might be used to select patients for trials of chemopreventive agents ( Figure 4 , Table 2 
Molecular markers of iCCA
Even fewer biomarkers of iCCA have been developed than for HCC; there is only level C data for the efficacy of a biomarker for this tumor type. iCCA is one of the few solid tumors for which no systemic molecular therapy has been approved by the Food and Drug Administration 13 .
Surgery is the only potentially curative option, although chemotherapy with gemcitabine plus cisplatin is the standard for patients with advanced-stage iCCA 162 . According to the ILCA practice guidelines, no studies have provided level A or B evidence for a marker of this tumorsome data from low-quality studies have led to weak recommendations 13 . These studies have been retrospective in design, without extensive validation in independent cohorts. Some gene expression and microRNA patterns have been associated with features of iCCA 85, 119, 123 , as well as mutations in KRAS and IDH1 or IDH2 and focal deletions at 14q22.1 85, 128, 129 ( Table 2) . Gene expression patterns have been reported to identify an iCCA proliferation subclass of tumor 85 , patients with a poor prognosis, 85, 123 and tumors with a stem cell-like subtype 119 , who have aggressive disease and worse outcome.
Features of cancer cells in a tumor determine not only the tumor's growth and progression, but also affect the tumor microenvironment (non-cancer cells and supporting stroma) 76 . Some studies associated features of the iCCA microenvironment with patient outcome 123, [163] [164] [165] . Two studies identified a stromal signature associated with shorter survival time by combining laser capture microdissection with gene expression profile analysis 123, 165 . Although many studies have validated gene expression signatures associated with patient outcomes, the clinical significance of microRNA signatures is not yet clear, due to the limited number of large comprehensive profiling studies 119, [166] [167] [168] .
Mutations in oncogenes such as KRAS and BRAF can be used to determine prognosis for patients with pancreatic or colorectal cancers [169] [170] [171] . 14, 136 .
Future Directions
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